Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity by Schwan, William R et al.
RESEARCH Open Access
Screening a mushroom extract library for activity
against Acinetobacter baumannii and Burkholderia
cepacia and the identification of a compound
with anti-Burkholderia activity
William R Schwan
1*, Craig Dunek
1,2, Michael Gebhardt
1, Kathleen Engelbrecht
1, Tiffany Klett
1, Aaron Monte
2,
Joseph Toce
2, Marc Rott
1, Thomas J Volk
3, John J LiPuma
4, Xue-Ting Liu
2, Ronald McKelvey
2
Abstract
Background: Acinetobacter baumannii and species within the Burkholderia cepacia complex (BCC) are significant
opportunistic bacterial pathogens of humans. These species exhibit a high degree of antibiotic resistance, and
some clinical isolates are resistant to all currently available antimicrobial drugs used for treatment. Thus, new drugs
are needed to treat infections by these species. Mushrooms could be a potential source for new drugs to treat A.
baumannii and BCC infections.
Methods: The aim of this study was to screen a library of crude extracts from 330 wild mushrooms by disk
diffusion assays for antibacterial activity against A. baumannii and Burkholderia cepacia in the hope of identifying a
novel natural drug that could be used to treat infections caused by these species. Once positive hits were
identified, the extracts were subjected to bioassay-guided separations to isolate and identify the active drug
molecules. MICs were performed to gauge the in vitro activity of the purified compounds.
Results: Only three crude extracts (0.9%) had activity against A. baumannii and B. cepacia. Compounds from two of
these extracts had MICs greater than 128 μg/ml, and further analyses were not performed. From the third extract,
prepared from Leucopaxillus albissimus, 2-aminoquinoline (2-AQ) was isolated. This compound exhibited a modest
MIC in vitro against strains from nine different BCC species, including multi-drug resistant clinical isolates (MIC = 8-
64 μg/ml), and a weak MIC (128 μg/ml) against A baumannii. The IC50 against a murine monocyte line was 1.5 mg/
ml.
Conclusion: The small number of positive hits in this study suggests that finding a new drug from mushrooms to
treat Gram-negative bacterial infections may be difficult. Although 2-AQ was identified in one mushroom, and it
was shown to inhibit the growth of multi-drug resistant BCC isolates, the relatively high MICs (8-128 μg/ml) for
both A. baumannii and BCC strains suggests that 2-AQ is not suitable for further drug development in its current
form.
Background
Glucose nonfermenting, Gram-negative rods (GNF-
GNR) are commonly found in the environment and are
typically responsible for opportunistic infections in
severely ill and immunocompromised patients. Because
this group of bacteria can survive in diverse
environments, they are important opportunistic patho-
gens [1,2]. Pseudomonas aeruginosa is a leading cause of
nosocomial infections due to GNF-GNR, followed by
Acinetobacter spp., Stenotrophomonas maltophilia,a n d
Alcaligenes spp. [3]. Although species in the Burkhol-
deria cepacia complex (BCC) do not often cause human
infections, it has been known for thirty years that infec-
tions that do occur are difficult to treat [4]. The BCC
c o m p r i s e sag r o u po fa tl e a s t1 7s p e c i e s[ 5 , 6 ] ,a l t h o u g h
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mon species recovered from cystic fibrosis (CF) patients
[4,7]. Besides CF patients, BCC also causes respiratory
infections in hospitalized immunocompromised patients
[8,9]. Some strains of the BCC are resistant to all known
antibiotics, including the front line drugs, trimethoprim/
sulfamethoxazole, piperacillin, ceftazidime, ciprofloxacin,
and pipericillin-tazobactam [10,11].
For the GNF-GNR, multidrug resistance is becoming
increasingly common [3,12]. This has led to the loss of
most classes of antibiotics to treat infections caused by
this group of bacteria, resulting in the use of polymyxins
as the only remaining option to treat many of the infec-
tions [12]. Unfortunately, polymyxins used for systemic
infections carry with them an increased risk of nephro-
toxicity in the patient population being treated. More-
over, BCC strains are inherently resistant to polymyxins.
Small molecules synthesized randomly through combi-
natorial chemistry techniques have been suggested as
one possible solution to bacterial drug resistance; how-
ever, these molecules generally lack the complexity of
those derived from natural sources [13,14]. Historically,
broad screening of natural products for antibacterial
activity has yielded many active compounds, with several
being derived from secondary metabolites of the myce-
lium of filamentous fungi [15]. In addition, because of
their natural resistance to degradation by many bacteria
in the soil, fungal fruiting bodies (i.e. mushrooms)
remain an untapped reservoir of novel natural products.
Moreover, it is estimated that only 5% of the approxi-
mately 1.5 million fungal species have been described
and chemically characterized [16]. Thus, wild mush-
rooms represent a potentially rich, untapped source of
new antimicrobial agents. In this study, we screened a
library of crude extracts from mushrooms for activity
against A. baumannii and B. cepacia, hoping to find a
new natural drug that could be used to treat infections
caused by multi-drug resistant strains of these species.
Methods
Construction of a mushroom crude extract library
Three hundred and thirty wild mushrooms were col-
lected from across the United States. Most the mush-
rooms were collected in Minnesota and Wisconsin,
although some were found in Colorado, Illinois, Michi-
gan, New Jersey, North Carolina, Oregon, Pennsylvania,
and Tennessee. A total of 59 different mushroom
families were represented in this collection. The family
Tricholomataceae was represented most often (26 mush-
rooms) followed by the family Agaricaceae (16 mush-
rooms). Mushroom sample weights from each site
ranged from 10 g to 70 g, representing one to 25 fruit-
ing bodies. Each mushroom was identified to the species
level based on the structural characteristics of the
fruiting body and air-dried in a commercially available
food dehydrator. Five grams of each dried fungal mate-
rial was extracted for 4 h at room temperature in the
dark with 20 mL of a 5% methanol-95% dichloro-
methane solution. After filtration, the volatiles were
removed by evaporation under a stream of N2 gas to
yield the crude extract in a tared glass vial.
Strains
The bacterial strains used in this study are listed in
Table 1. All Burkholderia strains were identified to the
species level at the Burkholderia cepacia Reference
Laboratory and Repository (University of Michigan) by
polyphasic analyses using phenotypic and genotypic
assays as described previously [8]. All Burkholderia iso-
lates also were subjected to repetitive extragenic ele-
ment-PCR typing using the BOX A1R primer as
previously described [17] to ensure that all isolates were
genotypically distinct. Bacteria were stored at -80°C in
skim milk or Luria-Bertani broth (Invitrogen) with 15%
glycerol and recovered from frozen stock overnight at
37°C on Mueller-Hinton (MH; Difco) agar. Bacteria
were grown on trypticase soy agar (BBL) overnight at
35°C before use in susceptibility testing.
Antimicrobial agents
The following antibiotics were used in Kirby Bauer disk
diffusion and MIC assays: tetracycline, trimethoprim-
sulfamethoxazole, tobramycin, gentamicin, amikacin,
aztreonam, ceftazidime, meropenem, imipenem, ticaricil-
lin/clavulonic acid, piperacillin/tazobactam, ciprofloxa-
cin, piperacillin, cefepime, and levofloxacin. The
antibiotics were purchased from Fluka or Sigma-Aldrich.
Disk diffusion assays
All Kirby Bauer disk diffusion assays were performed
according to Clinical and Laboratory Standards Institute
(CLSI) guidelines [18]. Tetracycline and dimethylsulfox-
ide (DMSO) were used as controls in these assays. A
zone of inhibition of growth greater than 6 mm was
considered positive in this screening procedure.
Bioassay-guided separation
For those extracts that showed a zone of inhibition of
growth of either A. baumannii UWL or B. cepacia
ATCC 25416, the extract was fractionated by successive
thin-layer chromatography (TLC), using 500 mm thick-
n e s sW h a t m a n2 0c m×2 0c m ,6 0Ås i l i c ag e lp l a t e s
with fluorescent indicator, eluting initially with 5%
methanol-95% dichloromethane and then 50% isopropa-
nol-50% acetonitrile. Following development of the TLC
plates, one fraction with activity against these bacteria
was visualized under short wave UV light (254 nm) as a
relatively low Rf, violet-colored band following develop-
ment of the TLC plates. Final purification of this bioac-
tive compound was accomplished by preparative scale
high performance liquid chromatography (HPLC) using
a Waters HPLC system with diode array detector,
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nia-55% methanol-44% water solution as the eluant. The
major component that eluted from the column retained
the previously observed bioactivity, and this purified
sample also was used for subsequent structure elucida-
tion studies. Structural analyses were performed using
positive ionization high-resolution mass spectrometry
(HRMS; Varian Saturn mass spectrophotometer), proton
and carbon NMR spectroscopy (500 MHz), and IR spec-
troscopy (thin film method).
MIC assays
All MIC assays were performed according to CLSI regu-
lations [18]. B. cepacia ATCC 25416 was used as a con-
trol for these assays. Each strain was tested a minimum
of three separate times to ensure reproducibility. Com-
mercially available 2-AQ (Sigma-Aldrich) was used in
side-by-side comparison testing with the naturally
derived 2-AQ and in the screening of several BCC
strains.
Cytotoxicity assays
To screen for cytotoxicity, two assays were used. The
first assay used sheep blood agar plates and two-fold
dilutions of the compound in phosphate buffered saline
(PBS, pH 7.2). Eight microliters of the diluted drug were
added to a 6 mm paper disk on a sheep blood agar
plate. The plates were incubated for 16 to 18 h at 35°C.
A zone of lysis was considered positive and the last dilu-
tion exhibiting a hemolysis zone was considered the
IC50 for the drug.
The second assay utilized was a trypan exclusion assay
[19]. Murine J774A.1 (ATCC) and human U937
(ATCC) monocyte cell lines were tested. Monocytes
were seeded at 1 × 10
6/well in a 24-well tissue culture
plate with RPMI 1640 medium (Invitrogen). The next
day, two-fold dilutions of the drug in PBS were added
to each well with RPMI 1640 medium. On the following
day, the spent medium was removed by aspiration and a
trypan blue solution was added to each well for 10 min.
After the 10 min elapsed, the trypan blue solution was
aspirated and an equal volume of PBS was added. Three
fields of cells were counted per well. The number of
dead (blue) and live (clear) cells was determined. An
IC50 was calculated for the well with 50% dead cells.
Results and Discussion
Screening the mushroom library
New drugs are needed to treat infections caused by
Gram-negative bacteria. The Antimicrobial Availability
Table 1 Bacteria used in this study
Bacteria Strain Source/reference
a
Achromobacter xylosoxidans MC MC
Achromobacter xylosoxidans ATCC 9220 ATCC
Acinetobacter baumannii UWL UWL
Acinetobacter baumannii ATCC 19606 ATCC
Burkholderia ambifaria AU4587 BcRLR
Burkholderia ambifaria AU5203 BcRLR
Burkholderia ambifaria AU11161 BcRLR
Burkholderia cepacia ATCC 25416 ATCC
Burkholderia cepacia AU0108 BcRLR
Burkholderia cepacia AU2720 BcRLR
Burkholderia cepacia AU2769 BcRLR
Burkholderia cepacia AU7554 BcRLR
Burkholderia cenocepacia J2315 BcRLR
Burkholderia cenocepacia AU6550 BcRLR
Burkholderia cenocepacia AU9292 BcRLR
Burkholderia cenocepacia AU10321 BcRLR
Burkholderia dolosa AU0794 BcRLR
Burkholderia dolosa AU3271 BcRLR
Burkholderia dolosa AU9336 BcRLR
Burkholderia dolosa AU9628 BcRLR
Burkholderia dolosa AU12872 BcRLR
Burkholderia gladioli AU3431 BcRLR
Burkholderia gladioli AU4123 BcRLR
Burkholderia gladioli AU9405 BcRLR
Burkholderia multivorans ATCC 27616 ATCC
Burkholderia multivorans AU5573 BcRLR
Burkholderia multivorans AU7455 BcRLR
Burkholderia multivorans AU10398 BcRLR
Burkholderia multivorans AU4507 BcRLR
Burkholderia pyroccinia AU5468 BcRLR
Burkholderia pyroccinia AU7314 BcRLR
Burkholderia pyroccinia AU1114 BcRLR
Burkholderia stabilis AU4757 BcRLR
Burkholderia stabilis AU5832 BcRLR
Burkholderia stabilis AU9035 BcRLR
Burkholderia vietnamiensis AU3032 BcRLR
Burkholderia vietnamiensis AU3578 BcRLR
Burkholderia vietnamiensis AU3997 BcRLR
Burkholderia vietnamiensis AU5003 BcRLR
Burkholderia vietnamiensis AU10214 BcRLR
Pseudomonas aeruginosa ATCC 27853 ATCC
Stenotrophomonas maltophilia UWL UWL
Stenotrophomonas maltophilia ATCC 13637 ATCC
a ATCC, American Type Culture Collection; BcRLR, Burkholderia cepacia
Research Laboratory and Repository (University of Michigan);UWL, the
University of Wisconsin-La Crosse Culture Collection; MC, Marshfield Clinic.
Schwan et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:4
http://www.ann-clinmicrob.com/content/9/1/4
Page 3 of 6Task Force (AATF) of the Infectious Diseases Society of
America (IDSA) has listed several microorganisms that
are viewed as significant health problems [20]. Among
the species listed are the GNF-GNR species P. aerugi-
nosa and A. baumannii, predominantly because of the
antibiotic resistance profiles for both species and the
dearth of potentially effective drugs in the late-stage
development pipeline. Moreover, extensively drug resis-
tant A. baumannii that are even resistant to colistin are
associated with high mortality rates [21]. In general, the
pipeline for viable/strong candidate antibacterial drugs is
lacking [22-24]. Currently, there are no new drugs with
novel mechanisms of action in Phase I clinical studies to
treat Gram-negative bacterial infections [25]. Further-
more, there are very few preclinical leads that exhibit
favorable profiles against Gram-negative bacteria.
In an attempt to find new drugs to treat infections
caused by GNF-GNR, 330 wild mushroom crude
extracts were tested for their activity against A. bau-
mannii UWL and B. cepacia ATCC 25416, but only
three extracts showed a zone of inhibition of growth
greater than 6 mm against both strains. The DMSO
controls displayed no zone of inhibition (reported as 6
mm), whereas tetracycline displayed a large inhibition
zone against both species. In the subsequent screening
of the three crude extracts, an extract from the Leuco-
paxillus albissimus mushroom was identified as the only
one showing promising activity against either A. bau-
mannii UWL or B. cepacia ATCC 25416 The zone of
antibacterial activity of this extract was larger against B.
cepacia compared to the zone for A. baumannii.
Purification of the active compound from an L. albissimus
crude extract
The major active component from L. albissimus was
determined to be 2-aminoquinoline (2-AQ), also known
as 2-quinolylamine, on the basis of its spectral and phy-
sical data. Its positive ionization high-resolution mass
spectrum (HRMS) showed an exact mass of 145.07573
g/mol for the M+1 ion, indicating a molecular formula
of C9H8N2 consistent with that of 2-AQ. The proton
and carbon NMR spectra were essentially identical to
those reported in the literature for 2-AQ [26]. The IR
spectrum (thin film method) of the natural product was
superimposable on the IR spectrum for 2-AQ contained
in the online SDBS spectral database. Finally, the HPLC
retention time and NMR spectra of the purified natural
product were compared with those of an authentic syn-
thetic sample obtained through Sigma-Aldrich, and
these were identical, as were the biological activities of
the two samples.
Antibacterial activity assessment of 2-AQ
Although antibacterial activity was previously attributed
to 2-AQ [26,27], GNF-GNR species, such as BCC, P.
aeruginosa, A. xylosoxidans, A. baumannii,a n dS.
maltophilia, were not tested in earlier studies. To deter-
mine the in vitro activity of the 2-AQ natural product, a
MIC analysis was performed to quantitatively measure
its activity against BCC species and other GNF-GNR
[13]. The MIC of 2-AQ for B. cepacia ATCC 25416 was
32 μg/ml, but it was 16 μg/ml for B. cenocepacia J2315
and B. multivorans ATCC 27616. The MIC of 2-AQ
was 64 μg/ml for S. maltophilia ATCC 13637, 32 μg/ml
for A. xylosoxidans ATCC 9220, and 128 μg/ml for both
P. aeruginosa ATCC 27853 and A. baumannii ATCC
19607 (TABLE 2). No inhibitory activity of 2-AQ was
observed for Escherichia coli, Staphylococcus aureus,o r
Enterococcus faecalis (data not shown). Commercially
available 2-AQ was also tested side-by-side with the nat-
ural product against the same species. No MIC differ-
ence was observed comparing the natural product to the
commercially prepared sample. The same bacterial
strains were tested against tetracycline, a drug class that
has been proven effective against a wide variety of GNF-
GNR bacteria, and the results are also shown in TABLE
2. Although tetracycline was more active against some
of the bacteria tested, the tetracycline MIC was equiva-
lent against B. cepacia ATCC 25416 (32 μg/ml), two- to
four-fold higher against the two A. xylosoxidans strains
(128 μg/ml), and four-fold higher against B. cenocepacia
J2315 when compared to the 2-AQ MIC (64 mg/ml). In
addition, the MICs of piperacillin and ceftazidime
against the ATCC strains of B. cepacia and P. aerugi-
nosa were both 1 μg/ml. Moreover, the MIC of sulfa-
methoxazole-trimethoprim (SXT) against B. cepacia
ATCC 25416 was 0.5 μg/ml.
To determine if 2-AQ had broad anti-Burkholderia
activity, a diverse panel of BCC strains as well as several
Burkholderia gladioli strains were tested using the com-
mercially prepared 2-AQ. These strains represented B.
Table 2 MICs of 2-aminoquinoline (2-AQ) isolated from L.
albissimus and tetracycline (Tc) against several bacterial
species
Species Strain MIC
a
2-AQ
b Tc
b
Pseudomonas aeruginosa ATCC 27853 128 8
Burkholderia cepacia ATCC 25416 32 32
Burkholderia cenocepacia J2315 16 64
Burkholderia multivorans ATCC 27616 16 2
Stenotrophomonas maltophilia UWL 32 0.25
Stenotrophomonas maltophilia ATCC 13637 64 1
Achromobacter xylosoxidans MC 64 128
Achromobacter xylosoxidans ATCC 32 128
Acinetobacter baumannii UWL 128 0.5
Acinetobacter baumannii ATCC 19606 128 2
a MIC given in μg/ml.
b 2-AQ,2-aminoquinoline; Tc, tetracycline.
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strains were environmental isolates, whereas others were
multi-drug and pan-drug resistant strains collected from
hospitalized patients. These results showed that there
was in vitro activity against B. gladioli and all of the
BCC strains (MICs of 16 to 64 μg/ml) (TABLE 3). Of
the species assayed, the five B. cepacia strains had the
lowest MIC range (8-32 μg/ml), whereas the B. stabilis
had the highest MICs (64 mg/ml). Multi-drug resistant
strains of B. ambifaria (AU5203 and AU11161), B. cepa-
cia (AU0108), B. cenocepacia (all strains except J2313),
B. dolosa (AU0936 and AU12872), B. multivorans
(AU4507, AU5573, AU7455, and AU10398), B. pyrocci-
nia (AU7324 and AU1114), B. stabilis (AU9035) and B.
vietnamiensis (AU10214) were examined in this study.
They all had 2-AQ susceptibility patterns similar to
non-multi-drug resistant environmental isolates.
Although B. gladioli i sn o tp a r to ft h eB C C ,t h es t r a i n s
that were tested also had high MICs (64 mg/ml). All of
the B. cenocepacia clinical isolates tested either dis-
played full resistance to all antibacterial drugs
(AU10321) or intermediate and full resistance (AU9292
and AU6550) to the same panel of 13 drugs that
included trimethoprim/sulfamethoxazole, tobramycin,
gentamicin, amikacin, aztreonam, piperacillin, piperacil-
lin/tazobactam, ticaricillin/clavulonic acid, ceftazidime,
cefepime, meropenem, imipenem, and levofloxacin
(TABLE 4) [28]. The in vitro activity of 2-AQ suggests
that the molecule has weak activity against bacterial
pathogens that affect CF patients, including highly drug
resistant strains of B. cepacia complex.
In vitro cytotoxicity testing of 2-AQ
A crude cytotoxicity test using sheep red blood cells
demonstrated that cell lysis occurred when the concen-
tration of 2-AQ was ≥ 1.6 mg/ml, suggesting that the
drug might have a low cytotoxic effect. Furthermore,
trypan blue exclusion experiments using 2-AQ against
J774A.1 and U937 murine monocytic cell lines demon-
strated that it took 1.5 mg/ml of 2-AQ to injure 50% of
the eukaryotic cells and 500 μg/ml to injure either cell
line. These results demonstrate that 2-AQ has a cyto-
toxicity profile against mammalian cells only 10 to 30-
fold higher than its MICs against GNF-GNR.
In this study, 2-AQ was identified as a natural product
that targets GNF-GNR, particularly the BCC. With the
number of multi-drug resistant BCC strains on the rise
[12,28,29], a new drug is sorely needed, particularly to
treat BCC strains that display resistance to the frontline
antibacterial drugs currently in use [29,30]. The in vitro
MIC values for 2-AQ were the lowest against the B.
cepacia strains within the BCC; however, they were still
too high to be considered for further commercial devel-
opment of 2-AQ in its current form. Furthermore, 2-
AQ is commercially available and is considered to be a
toxic compound. It is possible that an analog of 2-AQ
could be developed with a more favorable therapeutic
index. Presently, 2-AQ analogs are being developed as
melanin-concentrating hormone antagonists [31,32].
Conclusion
Screening of a library of wild mushroom extracts for
antibacterial activity against A. baumannii and B. cepa-
cia yielded limited results. Only three mushroom
extracts displayed any activity, and further investigation
of the mushroom with the most promising activity, L.
albissimus, resulted in the isolation of a known
Table 3 MIC range of commercially available 2-AQ
activities against Burkholderia strains
Species (μg/ml) Strains Tested MIC Range
B. ambifaria 3 16-64
B. cenocepacia 4 16-64
B. cepacia 5 8-32
B. dolosa 5 32-64
B. gladioli 36 4
B. multivorans 53 2
B. pyroccinia 3 32-64
B. stabilis 36 4
B. vietnamiensis 5 32-64
Table 4 Comparison of commercially prepared 2-AQ MICs versus frontline drug MICs against multidrug-resistant B.
cepacia complex clinical isolates
Antibacterial drug MIC (μg/ml)
Bacterial strain SXT
a NN GM AN ATM PIP TZP TIC CAZ FEP MEM IPM LVX 2-AQ
B. multivorans AU5573 0.25 256 64 64 16 32 8 128 8 8 4 32 1 64
B. multivorans AU7455 1 64 >64 >64 16 8 8 32 8 2 2 32 2 32
B. multivorans AU10398 1 >256 >64 >64 32 -
b 32 >128 >64 >32 8 16 16 16
B. cenocepacia AU6550 4 >256 >64 >64 >64 - 128 >128 16 >32 16 >32 16 16
B. cenocepacia AU9292 >4 >256 >64 >64 >64 >128 >128 >128 32 >32 16 >32 >16 64
B. cenocepacia AU10321 4 >256 >64 >64 >64 >64 >128 >128 64 >32 32 >32 >16 32
aSXT = trimethoprim/sulfa, NN = tobramycin, GM = gentamicin, AN = amikacin, ATM = aztreonam, PIP = piperacillin, TZP = piperacillin/tazobactam, TIC =
ticaricillin/clavulanic acid,, CAZ = ceftazidime, FEP = cefepime, MEM = meropenem, IPM = imipenem, LVX = levofloxacin, and 2-AQ = 2-aminoquinoline.
b - = not determined.
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eral BCC strains and limited potential for commercial
development.
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